Antigen BackgroundProgrammed death-ligand 1 (PD-L1), CD274 or B7 Homolog 1(B7-H1) is a protein encoded by the CD274 gene. When bound to its ligands, PD-1 and B7.1, it plays an immunosuppressive role by inhibiting T-cell activity. Overexpression of PD-L1 by cancer cells may enable them to evade the host immune response, conferring a growth advantage to such tumours. PD-L1 expression levels detected by immunohistochemistry can therefore be of progn...

7mL PD-L1 (73-10) Bond RTU Primary

NEWCASTLE, ENGLAND, UK NOVEMBER 2018 – Leica Biosystems, a leading provider of pathology products and solutions, globally launched a new PD-L1 antibody for use on their fully automated BOND IHC and ISH staining platform. The new PD-L1 (programmed death - ligand 1) antibody uses the MKP1A07310 (clone 73-10) expressed by UK - based Abcam on behalf of Merck KGaA, Darmstadt, Germany, which owns all IP rights to this antibody. It joins the recently released ALK (anaplastic lymphoma kinase) antibody as the latest addition to Novocastra’s growing lung menu of primary antibodies. Leica Biosystems’ Newcastle, UK team have deep knowledge and expertise in end-to-end antibody development and manufacturing, and have optimized these two clones into a ready-to-use format for use on the BOND ...

Antigen BackgroundPD-1 (Programmed Death 1) is a 55KDa Type I transmembrane cell surface receptor which is expressed by T-cells during activation. It is also upregulated in B-cells, dendritic cells, natural killer cells and some myeloid cells, suggesting a broad role for PD1 in immune regulation. PD-1 interacts with at least two ligands: PD-L1 and PD-L2. PD-1/PD-L1 interaction is important in many Tcell functions including acute and chronic infla...

It’s Time for TIME Alexander “Sandy” Borowsky Professor of Pathology and Laboratory Medicine Center for Immunology and Infectious Diseases Disclosures Bristol-Meyers Squibb/Celgene: Funded through Investigator Sponsored Research (ISR) program. Discovery proposal. Leica/Aperio: Funded to run the “Genesis” study for primary diagnosis from whole slide images. Honorarium for this presentation. Histolix: Slide-free histology (Levenson and Fereidouni). Pfizer: Pfizer Protocol A9001502, Treatment Resistance Following Therapies (TRANSLATE) site PI. Agenda: In contracting to join the “FLEX” registry. None of these has actually paid me, only funding for the research projects. Objectives • Introduction into the complexity of the TIME and the development of new cancer treatments though di...

Phenotyping Tumor Microenvironment Using DNA Barcoded Multiplex Technology Chifei Sun GSK IVIVTBIBCellular Biomarkers Collegeville, PA I have no conflict of interests with Leica Biosystems, Ultivue and Indica Labs. – All the materials used in this presentation are for educational purpose only. – The human biological samples were sourced ethically, and their research use was in accord with the terms of the informed consents under an IRB/EC approved protocol. Statement 9/25/2020 2 Understand the complexity of tumor microenvironment and its importance in drug development – Introduce the Ultivue DNA barcoding and exchange technology for multiplex immunofluorescence – Highlight the processes of image fusion, spatial analysis and colocalization of markers on individual cells Learnin...

The content of this webinar will encompass detailed technical descriptions of novel and state of the art methods to decalcify tissue samples that will be embedded in paraffin or for frozen sectioning for molecular and nucleic acid analysis for basic research...

Melbourne, Australia and Cambridge, Massachusetts – September 14, 2018 | Leica Biosystems and Ultivue begin Co-Marketing of UltiMapper™ Assay on the BOND RX enabling single-step automated multiplexing in under 6 hours. Building on its legacy of partnering with emerging technology leaders, Leica Biosystems have partnered with Ultivue and announced the co-marketing of Ultivue’s UltiMapper™ assays with Leica Biosystems’ BOND RX research staining platform1 enabling rapid automated multiplex biomarker detection. The Ultivue UltiMapper single step multiplexing assay is pre-optimized for the BOND RX enabling a fully automated plug-and-play solution resulting in the creation of 30, five color, high performance immunohistochemistry multiplexing slides in under 6 hours while preserving t...

The potential for non-invasive tests that provide equivalent research and diagnostic value as can be obtained from tissue biopsies is real, but not yet realized. Tissue biopsies allow for identification, phenotyping and molecular analysis of cancer and...

Introduction to immuno oncology 1. Introduction to Immuno-Oncology Michael Bates, MD Oncology Strategy, Medical and Scientific Affairs Cepheid Sunnyvale, CA Cepheid and Leica Biosystems are Danaher Companies 2. Overview • History of Immuno-Oncology • Types of Immunotherapy • Immunomodulatory agents • Personalized Cancer Vaccines • CAR-T cell therapy • Immune Checkpoint Inhibitors • Focus: Immune Checkpoint Biomarkers 3. Evolution of Cancer Immunotherapy • William Coley – 1890s surgeon • Coley’s toxin… • BCG, IFN-alpha, IL-2 • IL-2 applications in melanoma and RCC proved that advanced metastatic cancers can be controlled in some patients by stimulating T cells with cytokines • Critical development • CTLA-4 shown to be inhibitory for T cell responses by James Allison and Jeff Blu...